Understanding cardiovascular and thromboembolic events in patients with von Willebrand disease in the French West
Cardiovascular and Venous Thromboembolism Disease in Patients with Von Willebrand Disease in the French West
This study looks at how often blood clots and heart rhythm problems happen in adults with von Willebrand disease in the French West to better understand their risks.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Brest Academic / other |
| Locations | 6 sites (Angers and 5 other locations) |
| Trial ID | NCT05773638 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the frequency and characteristics of arterial and venous thromboembolic events, as well as atrial fibrillation, in adult patients with von Willebrand disease in the French West. It will utilize a retrospective multicenter approach, analyzing data from patients who have experienced thrombotic events while being treated at designated medical centers. The study seeks to fill the gap in existing literature regarding the management of thrombotic risks in this population, given their unique bleeding risk profile.
Who should consider this trial
Good fit: Ideal candidates for this study are adults diagnosed with von Willebrand disease who have experienced thrombotic or embolic events and are being followed at participating medical centers in the French West.
Not a fit: Patients with acquired von Willebrand syndrome or those under legal protection will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the understanding and management of thrombotic events in patients with von Willebrand disease, leading to better patient outcomes.
How similar studies have performed: While there is limited data on this specific population, similar studies on thromboembolic events in other bleeding disorders have shown promising results, indicating potential for valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Von Willebrand disease * Adult * Followed-up in a reference center of West of France (Caen, Brest, Nantes, Rennes, Le Mans, Angers) * Consented to be included in BERHLINGO database * Have presented a thrombotic and/or embolic event or cardiovascular disease including deep vein thrombosis, pulmonary embolism, ischemic stroke, transient ischemic attack, acute coronary syndrome, acute limb ischemia or angina or obliterating arteriopathy of the lower limbs, atrial fibrillation. * Have not expressed their opposition Exclusion Criteria: * \- Expression of opposition * Acquired von Willebrand syndrome * Patients under legal protection * Minor
Where this trial is running
Angers and 5 other locations
- CHU d'Angers — Angers, France (Not_yet_recruiting)
- CHU de Brest — Brest, France (Recruiting)
- CHU de Caen — Caen, France (Not_yet_recruiting)
- CH le MANS — Le Mans, France (Not_yet_recruiting)
- CHU de Nantes — Nantes, France (Not_yet_recruiting)
- CHU de Rennes — Rennes, France (Not_yet_recruiting)
Study contacts
- Study coordinator: Brigitte PAN PETESCH
- Email: brigitte.pan-petesch@chu-brest.fr
- Phone: 02.98.22.36.50
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.